Financials

News Ideas Discussions Technicals Seasonals

DMYD_B fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen, which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. The company also develops and invests in stem cell and medical technology. Diamyd Medical was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

DMYD_B has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company